Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer

被引：0

作者：

Rustin, G. J.

Reed, N. S.

Jayson, G.

Ledermann, J. A.

Adams, M.

Stredder, C.

Wagner, A.

Giurescu, M.

机构：

[1] Mt Vernon Canc Ctr, Northwood, Middx, England

[2] Beatson Oncol Ctr, Glasgow, Lanark, Scotland

[3] Christie Hosp, Manchester, Lancs, England

[4] UCL, London, England

[5] Velindre Hosp, Cardiff, S Glam, Wales

[6] Schering Hlth Care Ltd, Burgess Hill, W Sussex, England

[7] Bayer Schering Pharma AG, Berlin, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5527

引用

页数：1

共 50 条

[31] Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy
Morrow, Phuong K.
Divers, Stephen
Provencher, Louise
Luoh, Shiuh-Wen
Petrella, Teresa M.
Giurescu, Marius
Schmelter, Thomas
Wang, Yao
Hortobagyi, Gabriel N.
Vahdat, Linda T.
BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (03) : 837 - 842
[32] ZK-EPO, a novel epothilone derivative, exhibits significant tumor growth inhibition in a wide range of human tumor models.
Klar, U
Buchmann, B
Schwede, W
Skuballa, W
Lichtner, RB
Fichtner, I
Hoffmann, J
Bosslet, K
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9092S - 9092S
[33] A phase II trial of voreloxin in women with platinum-resistant ovarian cancer
Hirte, H. W.
McGuire, W.
Edwards, R.
Husain, A.
Hoskins, P.
Michels, J.
Matulonis, U.
Sexton, C.
Michelson, G.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[34] Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy
Phuong K. Morrow
Stephen Divers
Louise Provencher
Shiuh-Wen Luoh
Teresa M. Petrella
Marius Giurescu
Thomas Schmelter
Yao Wang
Gabriel N. Hortobagyi
Linda T. Vahdat
Breast Cancer Research and Treatment, 2010, 123 : 837 - 842
[35] ZK-EPO, a third-generation epothilone inhibits tumor growth and osteolysis in a mouse model of breast cancer bone metastasis
Kakonen, S.
Hoffmann, J.
Klar, U.
ANNALS OF ONCOLOGY, 2007, 18 : 35 - 35
[36] Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
Walsh, Christine S.
Kamrava, Mitchell
Rogatko, Andre
Kim, Sungjin
Li, Andrew
Cass, Ilana
Karlan, Beth
Rimel, Bobbie J.
PLOS ONE, 2021, 16 (06):
[37] A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer
Anda M. Vlad
Raluca A. Budiu
Diana E. Lenzner
Yun Wang
Julia A. Thaller
Kelly Colonello
Peggy A. Crowley-Nowick
Joseph L. Kelley
Fredric V. Price
Robert P. Edwards
Cancer Immunology, Immunotherapy, 2010, 59 : 293 - 301
[38] A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer
Vlad, Anda M.
Budiu, Raluca A.
Lenzner, Diana E.
Wang, Yun
Thaller, Julia A.
Colonello, Kelly
Crowley-Nowick, Peggy A.
Kelley, Joseph L.
Price, Fredric V.
Edwards, Robert P.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (02) : 293 - 301
[39] Molecular Mode of Action and Role of TP53 in the Sensitivity to the Novel Epothilone Sagopilone (ZK-EPO) in A549 Non-Small Cell Lung Cancer Cells
Winsel, Sebastian
Sommer, Anette
Eschenbrenner, Julia
Mittelstaedt, Kevin
Klar, Ulrich
Hammer, Stefanie
Hoffmann, Jens
PLOS ONE, 2011, 6 (04):
[40] Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
Robert J. Morgan
Timothy W. Synold
David Gandara
Franco Muggia
Sidney Scudder
Eddie Reed
Kim Margolin
James Raschko
Lucille Leong
Stephen Shibata
Merry Tetef
Steven Vasilev
Kathryn McGonigle
Jeff Longmate
Yun Yen
Warren Chow
George Somlo
Mary Carroll
James H. Doroshow
Cancer Chemotherapy and Pharmacology, 2004, 54 : 283 - 289

← 1 2 3 4 5 →